JS-K, a Glutathione S-Transferase–Activated Nitric Oxide Donor With Antineoplastic Activity in Malignant Gliomas

The Nitric Oxide Prodrug JS-K Is Effective against Non-Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species

(2010) A. E. Maciag et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas

(2010) A. Weyerbrock et al.   NEURO-ONCOLOGY

Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells

(2009) Jie Liu et al.   GENOMICS

Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-κB

(2009) W. Joon Chung et al.   JOURNAL OF NEUROCHEMISTRY

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)

(2009) Paul J. Shami et al.   LEUKEMIA RESEARCH

Stabilization of the Nitric Oxide (NO) Prodrugs and Anticancer Leads, PABA/NO and Double JS-K, through Incorporation into PEG-Protected Nanoparticles

(2009) Varun Kumar et al.   MOLECULAR PHARMACEUTICS

Role of soluble guanylyl cyclase–cyclic GMP signaling in tumor cell proliferation

(2009) Kalpana Mujoo et al.   NITRIC OXIDE-BIOLOGY AND CHEMISTRY

Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs

(2008) Harinath Chakrapani et al.   BIOORGANIC & MEDICINAL CHEMISTRY

cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines

(2008) G Haramis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Heterogeneity of Human Glioblastoma: Glutathione-S-Transferase and Methylguanine-Methyltransferase

(2008) Lucienne Juillerat-Jeanneret et al.   CANCER INVESTIGATION

Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro

(2008) Astrid Weyerbrock et al.   JOURNAL OF NEUROSURGERY

Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53

(2008) J Kitagaki et al.   ONCOGENE